Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Average Rating of “Moderate Buy” by Analysts

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $10.1667.

MRKR has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Monday, December 22nd. Zacks Research cut shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Wall Street Zen upgraded shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. UBS Group reissued a “buy” rating on shares of Marker Therapeutics in a research report on Monday, December 8th. Finally, HC Wainwright assumed coverage on shares of Marker Therapeutics in a research report on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective on the stock.

Institutional Investors Weigh In On Marker Therapeutics

A number of large investors have recently made changes to their positions in the business. Boyer Financial Services Inc. purchased a new position in shares of Marker Therapeutics during the fourth quarter valued at approximately $57,000. Virtu Financial LLC bought a new stake in Marker Therapeutics in the third quarter valued at $25,000. Two Sigma Investments LP purchased a new position in Marker Therapeutics during the 3rd quarter valued at $33,000. Finally, Jane Street Group LLC bought a new position in Marker Therapeutics in the 2nd quarter worth $33,000. 22.39% of the stock is currently owned by institutional investors.

Marker Therapeutics Stock Up 6.9%

Shares of NASDAQ:MRKR opened at $1.71 on Tuesday. The stock has a market cap of $28.51 million, a PE ratio of -1.39 and a beta of 1.44. The company’s fifty day moving average is $1.58 and its 200 day moving average is $1.25. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.57. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%.The firm had revenue of $1.23 million for the quarter, compared to analysts’ expectations of $0.72 million. Sell-side analysts anticipate that Marker Therapeutics will post -0.65 EPS for the current year.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.